| scholarly article | Q13442814 |
| P50 | author | Margaret M Redfield | Q98243295 |
| P2093 | author name string | Douglas L Mann | |
| Gregory D Lewis | |||
| Divya Gupta | |||
| Adam D DeVore | |||
| Adrian F Hernandez | |||
| Eugene Braunwald | |||
| Randall C Starling | |||
| Michael M Givertz | |||
| Patrice Desvigne-Nickens | |||
| Stephen J Greene | |||
| Eiran Z Gorodeski | |||
| Selma F Mohammed | |||
| LIFE Investigators | |||
| Andrew P Ambrosy | |||
| Claudius Mahr | |||
| Steven E McNulty | |||
| Palak Shah | |||
| Justin M Vader | |||
| Anuradha Lala | |||
| Nisha A Gilotra | |||
| P2860 | cites work | Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry | Q92857637 |
| Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction | Q93053031 | ||
| Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis | Q93365428 | ||
| Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee | Q95723047 | ||
| Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
| Combination of isosorbide dinitrate and hydralazine in blacks with heart failure | Q28292266 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 | ||
| Effect of carvedilol on survival in severe chronic heart failure | Q33949292 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut | Q34527664 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). | Q35035016 | ||
| Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial | Q38391338 | ||
| Oral levosimendan in patients with severe chronic heart failure --the PERSIST study | Q38572099 | ||
| Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years | Q38787758 | ||
| The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities | Q39361032 | ||
| Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials | Q41859441 | ||
| Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group | Q42547184 | ||
| Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). | Q43723547 | ||
| Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial | Q44732752 | ||
| The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial | Q48395213 | ||
| Outpatient Worsening Heart Failure as a Target for Therapy: A Review | Q49506557 | ||
| Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan | Q57396161 | ||
| Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine I | Q57396192 | ||
| 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure | Q57629858 | ||
| Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care | Q58610156 | ||
| Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | Q61795227 | ||
| Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group | Q67663743 | ||
| Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial | Q69888770 | ||
| Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group | Q71545362 | ||
| Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators | Q73217048 | ||
| 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society o | Q87967845 | ||
| Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction | Q90718817 | ||
| P921 | main subject | ejection fraction | Q641303 |
| heart failure with reduced ejection fraction | Q56218018 | ||
| P577 | publication date | 2020-06-10 | |
| P1433 | published in | JACC: Heart Failure | Q26841917 |
| P1476 | title | Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial |
| Q104074388 | Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels | cites work | P2860 |
Search more.